Antibodies against parp and caspase 3

Midostaurin, crenolanib, gilteritinib, quizartinib, sorafenib, CHIR-99021, and SB216763 were obtained from Selleck Chemicals (Houston, TX, USA). Homoharringtonine (HHT) injection solution was purchased from Minsheng Pharmaceutical Group (Hangzhou, China). Acridine orange (AO), 12-O-tetradecanoylphorbol 13-acetate (TPA), and ethidium bromide (EB) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Antibodies against PARP and caspase-3 were purchased from BD Biosciences (Maryland, USA); antibodies against Mcl-1 (S-19), Bcl-2 (C-2), and β-actin (C-2) were acquired from Santa Cruz Biotechnology (San Diego, CA); antibodies against FLT3 (8F2), phospho-FLT3 (Tyr589/591)(30D4), Axl (C89E7), phospho-Axl (Tyr698), phospho-AKT (Ser473), phospho-GSK3β (Ser9), phospho-ERK (Thr202/Tyr204), PUMA, Bim (C34C5), and cleaved caspase-3 were obtained from Cell Signaling Technology, Inc. (Beverly, MA); and siRNAs for AXL (sc-29769), MCL1 (sc-35877) and BIM (sc-29802) were obtained from Santa Cruz Biotechnology (San Diego, CA).

HHT for injection was purchased from Minsheng Pharmaceutical Group (Hangzhou, China). Cytarabine and PH797804 were obtained from Selleck Chemicals (Houston, TX, USA). SB203580 was acquired from Sigma–Aldrich, Inc. Antibodies against PARP and caspase-3 were purchased from BD Biosciences (Maryland, USA); antibodies against cleaved caspase-3 (C-C3), p-p38, p-JNK, ERK, p-ERK and p-H2AX were obtained from Cell Signaling Technology, Inc. (Beverly, MA); and antibodies against Mcl-1, p38α, JNK1 and β-actin were acquired from Santa Cruz Biotechnology (San Diego, CA).